Organovo Holdings Inc (ONVO) Stake Raised by Vanguard Group Inc

Vanguard Group Inc grew its position in Organovo Holdings Inc (NASDAQ:ONVO) by 1.1% during the 3rd quarter, according to the company in its most …

Organovo logoVanguard Group Inc grew its position in Organovo Holdings Inc (NASDAQ:ONVO) by 1.1% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 4,771,558 shares of the medical research company’s stock after acquiring an additional 52,073 shares during the quarter. Vanguard Group Inc owned about 4.12% of Organovo worth $5,487,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Virtu Financial LLC purchased a new stake in shares of Organovo in the third quarter valued at $138,000. Renaissance Technologies LLC raised its stake in shares of Organovo by 179.2% in the second quarter. Renaissance Technologies LLC now owns 1,244,600 shares of the medical research company’s stock valued at $1,742,000 after acquiring an additional 798,800 shares during the period. Vanguard Group Inc. raised its stake in shares of Organovo by 1.1% in the third quarter. Vanguard Group Inc. now owns 4,771,558 shares of the medical research company’s stock valued at $5,487,000 after acquiring an additional 52,073 shares during the period. BlackRock Inc. raised its stake in shares of Organovo by 14.8% in the second quarter. BlackRock Inc. now owns 6,966,411 shares of the medical research company’s stock valued at $9,753,000 after acquiring an additional 897,113 shares during the period. Finally, ARK Investment Management LLC raised its stake in shares of Organovo by 20.8% in the third quarter. ARK Investment Management LLC now owns 17,951,107 shares of the medical research company’s stock valued at $20,644,000 after acquiring an additional 3,090,669 shares during the period. 36.22% of the stock is currently owned by institutional investors and hedge funds.

Shares of NASDAQ ONVO traded up $0.01 during mid-day trading on Tuesday, reaching $1.01. The company had a trading volume of 11,445 shares, compared to its average volume of 560,614. The stock has a market cap of $119.49 million, a PE ratio of -3.16 and a beta of 1.84. Organovo Holdings Inc has a 52 week low of $0.90 and a 52 week high of $2.09.

Organovo (NASDAQ:ONVO) last posted its quarterly earnings results on Thursday, February 7th. The medical research company reported ($0.06) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.07) by $0.01. The firm had revenue of $0.78 million for the quarter, compared to analysts’ expectations of $0.87 million. Organovo had a negative net margin of 770.79% and a negative return on equity of 67.55%. Research analysts forecast that Organovo Holdings Inc will post -0.25 earnings per share for the current year.

Several equities research analysts have recently weighed in on ONVO shares. Zacks Investment Research downgraded shares of Organovo from a “buy” rating to a “hold” rating in a research note on Tuesday, February 5th. HC Wainwright initiated coverage on shares of Organovo in a report on Thursday, December 13th. They issued a “buy” rating and a $2.50 price target on the stock.

TRADEMARK VIOLATION NOTICE: This news story was originally published by Fairfield Current and is the property of of Fairfield Current. If you are reading this news story on another domain, it was stolen and republished in violation of US & international trademark and copyright laws. The correct version of this news story can be accessed at https://www.fairfieldcurrent.com/news/2019/02/12/organovo-holdings-inc-onvo-stake-raised-by-vanguard-group-inc.html.

Organovo Company Profile

Organovo Holdings, Inc, a biotechnology company, provides therapeutic and drug profiling capabilities based on its 3D bioprint tissues that emulate human biology and diseases. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture.

Featured Article: Intrinsic Value

Want to see what other hedge funds are holding ONVO?Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Organovo Holdings Inc (NASDAQ:ONVO).

Institutional Ownership by Quarter for Organovo (NASDAQ:ONVO)

Receive News & Ratings for Organovo Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Organovo and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

Renaissance Technologies LLC Boosts Holdings in Organovo Holdings Inc (NASDAQ:ONVO)

Renaissance Technologies LLC lifted its position in shares of Organovo Holdings Inc (NASDAQ:ONVO) by 25.4% during the third quarter, according to …

Organovo logoRenaissance Technologies LLC lifted its position in shares of Organovo Holdings Inc (NASDAQ:ONVO) by 25.4% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,561,000 shares of the medical research company’s stock after purchasing an additional 316,400 shares during the quarter. Renaissance Technologies LLC owned 1.35% of Organovo worth $1,795,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of ONVO. ARK Investment Management LLC lifted its holdings in Organovo by 20.8% in the 3rd quarter. ARK Investment Management LLC now owns 17,951,107 shares of the medical research company’s stock valued at $20,644,000 after purchasing an additional 3,090,669 shares in the last quarter. BlackRock Inc. raised its holdings in shares of Organovo by 1.5% during the 3rd quarter. BlackRock Inc. now owns 7,068,897 shares of the medical research company’s stock worth $8,129,000 after acquiring an additional 102,486 shares during the period. Finally, Virtu Financial LLC purchased a new position in shares of Organovo during the 3rd quarter worth $138,000. 36.22% of the stock is currently owned by institutional investors and hedge funds.

Several research analysts have recently commented on ONVO shares. Zacks Investment Research lowered Organovo from a “buy” rating to a “hold” rating in a report on Tuesday, February 5th. HC Wainwright started coverage on Organovo in a report on Thursday, December 13th. They set a “buy” rating and a $2.50 price target on the stock.

NASDAQ ONVO opened at $1.00 on Tuesday. The stock has a market capitalization of $119.49 million, a price-to-earnings ratio of -3.13 and a beta of 1.84. Organovo Holdings Inc has a 1-year low of $0.90 and a 1-year high of $2.09.

Organovo (NASDAQ:ONVO) last released its earnings results on Thursday, February 7th. The medical research company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.07) by $0.01. The company had revenue of $0.78 million during the quarter, compared to the consensus estimate of $0.87 million. Organovo had a negative return on equity of 67.55% and a negative net margin of 770.79%. Equities research analysts anticipate that Organovo Holdings Inc will post -0.25 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “Renaissance Technologies LLC Boosts Holdings in Organovo Holdings Inc (NASDAQ:ONVO)” was originally published by Fairfield Current and is owned by of Fairfield Current. If you are accessing this news story on another publication, it was illegally stolen and republished in violation of international trademark & copyright law. The correct version of this news story can be read at https://www.fairfieldcurrent.com/news/2019/02/12/renaissance-technologies-llc-boosts-stake-in-organovo-holdings-inc-onvo.html.

Organovo Profile

Organovo Holdings, Inc, a biotechnology company, provides therapeutic and drug profiling capabilities based on its 3D bioprint tissues that emulate human biology and diseases. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture.

Featured Article: How to Use the New Google Finance Tool

Institutional Ownership by Quarter for Organovo (NASDAQ:ONVO)

Receive News & Ratings for Organovo Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Organovo and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

Renaissance Technologies LLC Has $1.80 Million Stake in Organovo Holdings Inc (NASDAQ:ONVO)

Renaissance Technologies LLC boosted its position in Organovo Holdings Inc (NASDAQ:ONVO) by 25.4% in the 3rd quarter, according to the …

Organovo logoRenaissance Technologies LLC boosted its position in Organovo Holdings Inc (NASDAQ:ONVO) by 25.4% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,561,000 shares of the medical research company’s stock after purchasing an additional 316,400 shares during the period. Renaissance Technologies LLC owned approximately 1.35% of Organovo worth $1,795,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. BlackRock Inc. raised its stake in shares of Organovo by 1.5% during the third quarter. BlackRock Inc. now owns 7,068,897 shares of the medical research company’s stock valued at $8,129,000 after acquiring an additional 102,486 shares in the last quarter. Virtu Financial LLC bought a new position in Organovo in the third quarter worth approximately $138,000. Finally, ARK Investment Management LLC raised its stake in Organovo by 20.8% in the third quarter. ARK Investment Management LLC now owns 17,951,107 shares of the medical research company’s stock worth $20,644,000 after buying an additional 3,090,669 shares in the last quarter. 36.15% of the stock is owned by institutional investors and hedge funds.

Several equities analysts have issued reports on the stock. Zacks Investment Research raised shares of Organovo from a “hold” rating to a “buy” rating and set a $1.25 price target on the stock in a report on Thursday, October 11th. HC Wainwright initiated coverage on shares of Organovo in a report on Thursday, December 13th. They set a “buy” rating and a $2.50 price objective on the stock.

NASDAQ ONVO opened at $1.01 on Monday. The firm has a market cap of $117.05 million, a P/E ratio of -3.16 and a beta of 1.84. Organovo Holdings Inc has a 1 year low of $0.90 and a 1 year high of $2.09.

Organovo (NASDAQ:ONVO) last issued its quarterly earnings data on Thursday, November 8th. The medical research company reported ($0.05) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.03. The business had revenue of $0.94 million during the quarter, compared to the consensus estimate of $0.90 million. Organovo had a negative net margin of 732.47% and a negative return on equity of 65.73%. Equities analysts anticipate that Organovo Holdings Inc will post -0.25 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Renaissance Technologies LLC Has $1.80 Million Stake in Organovo Holdings Inc (NASDAQ:ONVO)” was first reported by Fairfield Current and is the sole property of of Fairfield Current. If you are viewing this report on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark law. The legal version of this report can be read at https://www.fairfieldcurrent.com/news/2019/02/04/renaissance-technologies-llc-boosts-stake-in-organovo-holdings-inc-onvo.html.

Organovo Profile

Organovo Holdings, Inc, a biotechnology company, provides therapeutic and drug profiling capabilities based on its 3D bioprint tissues that emulate human biology and diseases. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture.

Read More: What is the float in trading stocks?

Institutional Ownership by Quarter for Organovo (NASDAQ:ONVO)

Receive News & Ratings for Organovo Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Organovo and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

BlackRock Inc. Increases Position in Organovo Holdings Inc (ONVO)

BlackRock Inc. lifted its holdings in Organovo Holdings Inc (NASDAQ:ONVO) by 14.8% during the 2nd quarter, according to the company in its most …

Organovo logoBlackRock Inc. lifted its holdings in Organovo Holdings Inc (NASDAQ:ONVO) by 14.8% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,966,411 shares of the medical research company’s stock after buying an additional 897,113 shares during the period. BlackRock Inc. owned approximately 6.27% of Organovo worth $9,753,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also bought and sold shares of the company. LPL Financial LLC lifted its stake in shares of Organovo by 61.9% in the first quarter. LPL Financial LLC now owns 123,023 shares of the medical research company’s stock worth $127,000 after buying an additional 47,042 shares in the last quarter. UBS Group AG lifted its stake in shares of Organovo by 44.4% in the first quarter. UBS Group AG now owns 888,385 shares of the medical research company’s stock worth $915,000 after buying an additional 273,029 shares in the last quarter. Finally, ARK Investment Management LLC lifted its stake in shares of Organovo by 32.1% in the second quarter. ARK Investment Management LLC now owns 14,860,438 shares of the medical research company’s stock worth $20,805,000 after buying an additional 3,614,856 shares in the last quarter. 33.38% of the stock is currently owned by hedge funds and other institutional investors.

ONVO has been the topic of several research reports. Jefferies Financial Group reissued a “buy” rating and issued a $1.75 price target on shares of Organovo in a research note on Friday, July 27th. Zacks Investment Research raised shares of Organovo from a “sell” rating to a “hold” rating in a research note on Saturday, September 1st.

Shares of ONVO stock opened at $1.14 on Friday. Organovo Holdings Inc has a 12 month low of $0.91 and a 12 month high of $2.09.

Organovo (NASDAQ:ONVO) last issued its earnings results on Thursday, November 8th. The medical research company reported ($0.05) EPS for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.03. Organovo had a negative net margin of 732.47% and a negative return on equity of 63.54%. The company had revenue of $0.94 million for the quarter, compared to the consensus estimate of $0.90 million. As a group, sell-side analysts forecast that Organovo Holdings Inc will post -0.29 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally published by Fairfield Current and is owned by of Fairfield Current. If you are viewing this piece of content on another publication, it was copied illegally and republished in violation of United States & international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.fairfieldcurrent.com/2018/11/11/blackrock-inc-increases-holdings-in-organovo-holdings-inc-onvo.html.

About Organovo

Organovo Holdings, Inc, a biotechnology company, provides therapeutic and drug profiling capabilities based on its 3D bioprint tissues that emulate human biology and diseases. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture.

Further Reading: How is a Moving Average Calculated?

Institutional Ownership by Quarter for Organovo (NASDAQ:ONVO)

Receive News & Ratings for Organovo Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Organovo and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts